scholarly journals Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
A. Kantele ◽  
M. P. Häkkinen ◽  
J. Zivny ◽  
C. O. Elson ◽  
J. Mestecky ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Cancer Vaccines ◽  
Tumor Antigens ◽  
The Body ◽  
Specific Response ◽  
Keyhole Limpet Haemocyanin ◽  
Protein Carrier ◽  
Humoral Immune ◽  
Immune Response To Cancer

Keyhole limpet haemocyanin (KLH) appears to be a promising protein carrier for tumor antigens in numerous cancer vaccine candidates. The humoral immune response to KLH was characterized at the single-cell level with ELISPOT combined with separations of cell populations according to their expression of homing receptors (HRs). The analysis of HR expressions is expected to reveal the targeting of the immune response in the body. Eight orally primed and four nonprimed volunteers received KLH-vaccine subcutaneously. Circulating KLH-specific plasmablasts were found in all volunteers, 60 KLH-specific plasmablasts/106PBMC in the nonprimed and 136/106in the primed group. The proportion of L-selectin+plasmablasts proved high and integrinα4β7+low. KLH serving as protein carrier in several vaccines, the homing profile of KLH-specific response may be applicable to the cancer antigen parts in the same vaccines. The present data reflect a systemic homing profile, which appears advantageous for the targeting of immune response to cancer vaccines.

Vaccination strategies in atherosclerosis

2011 ◽  
Vol 106 (11) ◽  
pp. 796-803 ◽  
Author(s):  
Johan Kuiper ◽  
Saskia de Jager
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Specific Antigen ◽  
The Body ◽  
Lipid Lowering ◽  
Current Status ◽  
Passive Immunisation ◽  
Humoral Immune ◽  
Vaccination Strategies ◽  
Self Antigens

SummaryThe treatment of atherosclerosis is currently based on lipid lowering in combination with anti-inflammatory therapies that slow the progression of atherosclerosis. Still, we are not able to fully inhibit the formation or progression of atherosclerotic lesions. A very effective strategy in other disease pathologies is vaccination, in which the body is challenged with the culprit protein or micro-organism in order to create a highly specific humoral immune-response. Immunisation can typically be divided into active or passive immunisation. Active immunisation occurs naturally when the body is exposed to certain microbes or antigens, but also artificially in the case of vaccination. Exposure to a microbe or antigen will result in the production of (antigen specific) antibodies. Passive immunisation is defined as the transfer of humoral immunity (as a result of antibody transfer). Another mechanism to ensure immune-protection is tolerance induction. Immune tolerance occurs naturally to prevent immune responses to ‘self-antigens’, but can also be induced to non-self antigens. Acquired tolerance to foreign antigens is accompanied by suppression of cellular and/or humoral immune response to the introduced antigen. In its most effective way, vaccination can result in a lifelong protection against the targeted pathology, and therefore the development of an atherosclerosis-specific vaccination is of high importance in the future prevention of atherosclerosis. One of the difficulties in developing effective vaccination strategies for atherosclerosis is the selection of a specific antigen to target. So far vaccination strategies have been based on targeting of lipidantigens, inflammation-derived antigens, and recently cell-based vaccination strategies have been employed; but also the cardiovascular ‘side-effects’ of infection-based vaccines are worthy of our attention. This review describes the current status-quo on classical antibody associated vaccination strategies but also includes promising immunemodulation approaches that may lead to a clinical application.

scholarly journals Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

2015 ◽  
Vol 21 (16) ◽  
pp. 3619-3630 ◽  
Author(s):  
Debraj GuhaThakurta ◽  
Nadeem A. Sheikh ◽  
Li-Qun Fan ◽  
Harini Kandadi ◽  
T. Craig Meagher ◽  
...  
Keyword(s):  
Immune Response ◽  
Clinical Outcome ◽  
Humoral Immune Response ◽  
Tumor Antigens ◽  
Humoral Immune

A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display

2006 ◽  
Vol 30 (3) ◽  
pp. 248-256 ◽  
Author(s):  
Emiliano Pavoni ◽  
Andrea Pucci ◽  
Paola Vaccaro ◽  
Giorgia Monteriù ◽  
Adolfo De Pasquale Ceratti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Phage Display ◽  
Cancer Patients ◽  
Humoral Immune Response ◽  
Tumor Antigens ◽  
Human Tumor ◽  
Breast Cancer Patients ◽  
Humoral Immune

Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA)

2008 ◽  
Vol 393 (2) ◽  
pp. 95-102 ◽  
Author(s):  
Bechr Hamrita ◽  
Karim Chahed ◽  
Maria Kabbage ◽  
Christelle Lemaitre Guillier ◽  
Mounir Trimeche ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Cancer Patients ◽  
Humoral Immune Response ◽  
Tumor Antigens ◽  
Proteome Analysis ◽  
Breast Cancer Patients ◽  
Humoral Immune

Significance of humanized mouse models for evaluating humoral immune response against cancer vaccines

2018 ◽  
Vol 7 ◽  
pp. 13-18 ◽  
Author(s):  
Yoshie Kametani ◽  
Asuka Miyamoto ◽  
Toshiro Seki ◽  
Ryoji Ito ◽  
Sonoko Habu ◽  
...  
Keyword(s):  
Immune Response ◽  
Mouse Models ◽  
Humoral Immune Response ◽  
Cancer Vaccines ◽  
Humanized Mouse ◽  
Humoral Immune ◽  
Humanized Mouse Models

Assessment of the humoral immune response to cancer

2012 ◽  
Vol 75 (15) ◽  
pp. 4573-4579 ◽  
Author(s):  
Mairead Anne Murphy ◽  
John James O'Leary ◽  
Dolores Josephine Cahill
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Humoral Immune ◽  
Immune Response To Cancer
Sign in / Sign up

Export Citation Format

Share Document